Cargando…

Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice

Detalles Bibliográficos
Autores principales:	Weidner, Heike, Wobus, Manja, Hofbauer, Lorenz C., Rauner, Martina, Platzbecker, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613459/ https://www.ncbi.nlm.nih.gov/pubmed/36175549 http://dx.doi.org/10.1038/s41375-022-01702-1

Ejemplares similares

Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells
por: Wobus, Manja, et al.
Publicado: (2021)

Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway
por: Balaian, Ekaterina, et al.
Publicado: (2018)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Machine learning assisted real-time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes
por: Herbig, Maik, et al.
Publicado: (2022)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

Transferrin receptor 2 deficiency promotes macrophage polarization and inflammatory arthritis
por: Ledesma-Colunga, Maria G., et al.
Publicado: (2023)

Mice lacking DKK1 in T cells exhibit high bone mass and are protected from estrogen-deficiency-induced bone loss
por: Lehmann, Juliane, et al.
Publicado: (2021)

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
por: Oliva, Esther Natalie, et al.
Publicado: (2021)

Loss of Dkk-1 in Osteocytes Mitigates Alveolar Bone Loss in Mice With Periodontitis
por: Goes, Paula, et al.
Publicado: (2019)

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
por: Komrokji, Rami S., et al.
Publicado: (2023)

P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY
por: Aluri, Srinivas, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study
por: Platzbecker, Uwe, et al.
Publicado: (2022)

Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept
por: Delanghe, Sigurd, et al.
Publicado: (2022)

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Myelodysplastic Syndromes and Metabolism
por: Balaian, Ekaterina, et al.
Publicado: (2021)

Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes
por: Chen, Nianhang, et al.
Publicado: (2020)

Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series
por: Khan, Shamis, et al.
Publicado: (2022)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
por: Hatzimichael, Eleftheria, et al.
Publicado: (2022)

Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
por: Bains, Amanpreet Kaur, et al.
Publicado: (2022)

Effects of adipocyte-specific Dkk1 deletion on bone homeostasis and obesity-induced bone loss in male mice
por: Daamouch, Souad, et al.
Publicado: (2023)

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
por: Garcia-Manero, Guillermo, et al.
Publicado: (2022)

Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study
por: Germing, Ulrich, et al.
Publicado: (2023)

Contributions of Dickkopf‐1 to Obesity‐Induced Bone Loss and Marrow Adiposity
por: Colditz, Juliane, et al.
Publicado: (2020)

Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans
por: Thiele, Sylvia, et al.
Publicado: (2019)

Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts
por: Huber, Sandra, et al.
Publicado: (2022)

The Bone Morphogenetic Protein Pathway: The Osteoclastic Perspective
por: Lademann, Franziska, et al.
Publicado: (2020)

Deconstructing cellular senescence in bone and beyond
por: Hofbauer, Lorenz C., et al.
Publicado: (2023)

Facing the challenge: Novel treatment options for patients with myelodysplastic syndromes
por: Kubasch, Anne Sophie, et al.
Publicado: (2018)

P733: TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN ROUTINE CLINICAL PRACTICE IN THE UNITED STATES
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

Luspatercept‐induced reduction in transfusion requirement in α‐thalassemia
por: Jackson, Nicholas, et al.
Publicado: (2020)

P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Old Dogs, New Tricks: Revisiting Immune Modulatory Approaches for Myelodysplastic Syndromes
por: Götze, Katharina S., et al.
Publicado: (2018)

Thy-1 Deficiency Augments Bone Loss in Obesity by Affecting Bone Formation and Resorption
por: Picke, Ann-Kristin, et al.
Publicado: (2018)

S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
por: Della Porta, Matteo Giovanni, et al.
Publicado: (2023)

MicroRNA and Diabetic Bone Disease
por: Daamouch, Souad, et al.
Publicado: (2022)

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO
por: Kubasch, Anne Sophie, et al.
Publicado: (2022)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
por: Musallam, Khaled M., et al.
Publicado: (2023)

Current challenges and unmet medical needs in myelodysplastic syndromes
por: Platzbecker, Uwe, et al.
Publicado: (2021)

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
por: Delgado, Julio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pjr2agef5o83rm2v2c2plbugnh